Latest news with #Vyjuvek
Yahoo
05-08-2025
- Health
- Yahoo
Dystrophic Epidermolysis Bullosa Market Analysis and Forecast, 2025-2035: Topical Therapies Dominate DEB Market as Vyjuvek Secures Leading Position
The global dystrophic epidermolysis bullosa (DEB) market is expanding due to increased awareness, advanced diagnostics, and innovative treatments like Vyjuvek, a topical gene therapy by Krystal Biotech. DEB, a rare genetic condition causing fragile skin, is being diagnosed earlier thanks to improved genetic screening and non-invasive imaging. However, the high costs and limited options for advanced disease stages remain challenges. North America leads the market with superior healthcare infrastructure and ongoing clinical research. The demand for DEB treatments is rising, driven by gene and cell-based solutions. Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Dystrophic Epidermolysis Bullosa Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to global dystrophic epidermolysis bullosa market is driven by rising awareness, advances in early diagnosis, and improved treatment options. DEB, a rare genetic disorder characterized by fragile skin that blisters easily, significantly impairs quality of life and can lead to severe complications such as chronic wounds, scarring, and increased risk of infections. Advances in genetic screening, biomarkers, and non-invasive imaging techniques are enabling earlier and more accurate diagnoses, which is driving the demand for more targeted therapeutic interventions. Additionally, innovations in gene therapy, such as Vyjuvek, and cell-based treatments are offering new hope for patients, improving skin healing and reducing the burden of the challenges including the high costs of novel therapies, limited treatment options for advanced stages of the disease, and variability in patient responses complicate treatment regimens for dystrophic epidermolysis bullosa. Additionally, the rarity of the condition and disparities in healthcare infrastructure limit access to timely and standardized care, especially in low- and middle-income countries. Despite these obstacles, increasing government and private sector investments in rare disease research, along with rising awareness campaigns, are driving market growth by improving early diagnosis, enhancing patient access to treatments for Dystrophic Epidermolysis Bullosa (DEB), such as gene therapies such as Vyjuvek, significantly improve skin healing and reduce blistering, enhancing patients' quality of life. Early diagnosis through advanced genetic screening and non-invasive imaging enables personalized care, while digital health tools and telemedicine improve monitoring and treatment adherence. These advancements are transforming DEB into a more manageable condition, improving patient outcomes and reducing healthcare topical therapies hold the highest market share. This can be attributed to the approval and adoption of Vyjuvek (eremagene geperpavec), a topical gene therapy developed by Krystal Biotech. This approval has positioned Vyjuvek as a leading treatment option, contributing to the dominance of topical therapies in the DEB America holds the highest market share in the dystrophic epidermolysis bullosa market, driven by the region's advanced healthcare infrastructure, robust reimbursement policies, and the presence of leading pharmaceutical companies actively developing and commercializing DEB therapies. Additionally, North America benefits from a high prevalence of DEB, extensive clinical research activities, and a well-established patient support network, all contributing to its leading position in the Drivers for the Global Dystrophic Epidermolysis Bullosa Market: Growing awareness is leading to earlier diagnosis and more identified cases of DEB. Gene therapies and cell-based treatments such as Vyjuvek are addressing DEB's genetic roots, creating demand for innovative solutions. Enhanced diagnostic tools enable quicker and more accurate identification of DEB. Early detection facilitates timely intervention, driving treatment demand. Global initiatives supporting rare diseases, including DEB, are increasing treatment access. Limitations for the Global Dystrophic Epidermolysis Bullosa Market: Advanced therapies, such as gene and cell-based treatments, come with high price tags, limiting their accessibility. Despite progress, gene and cell-based therapies for DEB are still in the early stages of development and are not widely available. The approval process for novel therapies in DEB can be slow and complex, hindering the timely availability of new treatments. Key Market Players and Competition SynopsisA detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global dystrophic epidermolysis bullosa market. Leading players in the global dystrophic epidermolysis bullosa market include: Krystal Biotech Castle Creek Biosciences Abeona Therapeutics Amryt Pharma Phoenix Tissue Repair InMed Pharmaceuticals Eloxx Pharmaceuticals RegeneRx Biopharmaceuticals Phoenicis Therapeutics BPGbio Key Topics Covered:1. Global Dystrophic Epidermolysis Bullosa Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.4 Regulatory Landscape1.5 Pipeline Analysis1.6 Market Dynamics2. Global Dystrophic Epidermolysis Bullosa Market (by Therapy Type), Value ($million), 2023-20352.1 Gene Therapy2.2 Cell-Based Therapy2.3 Topical Therapies2.4 Small Molecule Therapy2.5 Others3. Global Dystrophic Epidermolysis Bullosa Market (by Region), Value ($Million), 2023-20353.1 North America3.2 Europe3.3 Asia-Pacific3.4 Rest-of-the-World4. Competitive Landscape and Company Profiles4.1 Competitive Landscape4.1.1 Mergers and Acquisitions4.1.2 Partnership, Alliances and Business Expansion4.1.3 New Offerings4.1.4 Regulatory Activities4.1.5 Funding Activities4.2 Company Profiles Krystal Biotech Castle Creek Biosciences Abeona Therapeutics Amryt Pharma Phoenix Tissue Repair InMed Pharmaceuticals Eloxx Pharmaceuticals RegeneRx Biopharmaceuticals Phoenicis Therapeutics BPGbio For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Belfast Telegraph
18-05-2025
- Health
- Belfast Telegraph
Cutting-edge medicines hoped to transform treatment of incurable skin condition
Debra, which supports 300 people living with epidermolysis bullosa (EB) in Ireland, said the entry of Filsuvez into the Irish market will ease the extreme pain endured by those with 'Butterfly Skin'. The disease is caused by the absence of proteins between the skin layers, making the skin ultra fragile and easy to wound. The charity insists that the expected introduction of the prescription medical gel before the end of the year could pave the way for gene therapy treatments, such as Vyjuvek. Sinead Hickey, head of research at Debra, said: 'Where Filsuvez is a promising start, as it can offer temporary pain relief, we hope it will mark the beginning for the treatment of rare disease in Ireland. 'Vyjuvek has the potential to provide life-changing wound healing for people living with Dystrophic EB, it has already proven to be very effective in the US.' The topical gel delivers new COL7A1 genes directly to skin wounds to promote wound healing. Ms Hickey said it does not have to be applied by a medical practitioner but can be done by a trained individual or family member. 'Unfortunately, Ireland is one of the slowest countries in Europe to move from recommendation to market and it could still be between seven and 12 years before we see Vyjuvek available to people here,' she said. Filsuvez, meanwhile, is applied to a sterile non-adhesive wound dressing or directly to the skin to ease the extreme pain of wounds caused by EB. Debra made submissions to the NCPE (National Centre for Pharmacoeconomics), which has recommended the HSE provides the gel once agreement is reached on pricing. A timeline has yet to be announced but Debra is optimistic a resolution will be found by the end of summer. The charity's chief executive, Jimmy Fearon, said its entry into the Irish market is a step in the right direction. 'The treatment for EB hasn't advanced much over time, so new treatments always bring hope,' he said. 'This is not a cure but it may reduce the equivalent of a bandage change every two weeks, providing some pain alleviation. 'What this primarily represents is hope, breaking through the glass ceiling would hopefully mean that others will follow. 'Debra and other EB charities around the world support and invest in important research but, ultimately, it's the pharmaceutical companies and venture capitalists that run the breakthrough.' Ireland is in the lowest quartile in Europe for introducing new drugs to the market, the chief executive said. 'It's an arduous process to bring a drug to market and this is a positive step,' added Mr Fearon. 'What we really need is faster progression from recommendation to market – time is of the essence for the 300 people in Ireland living in pain due to this condition.'
The Journal
18-05-2025
- Health
- The Journal
Cutting-edge medicines hoped to transform treatment of incurable skin condition EB
THE INTRODUCTION OF two new cutting-edge medicines are hoped to transform the treatment of a rare incurable skin condition, a charity has said. Debra, which supports 300 people living with epidermolysis bullosa (EB) in Ireland, said the entry of Filsuvez into the Irish market will ease the extreme pain endured by those with 'Butterfly Skin'. The disease is caused by the absence of proteins between the skin layers, making the skin ultra fragile and easy to wound. The charity insists that the expected introduction of the prescription medical gel before the end of the year could pave the way for gene therapy treatments, such as Vyjuvek. Sinead Hickey, head of research at Debra, said: 'Where Filsuvez is a promising start, as it can offer temporary pain relief, we hope it will mark the beginning for the treatment of rare disease in Ireland. 'Vyjuvek has the potential to provide life-changing wound healing for people living with Dystrophic EB, it has already proven to be very effective in the US.' Actor Colin Farrell with his friend Emma Fogarty, running in the Irish Life Dublin Marathon in Dublin in October, to raise money for people living with Epidermolysis Bullosa (EB), a rare genetic skin condition suffered by Ms Fogarty. Alamy Stock Photo Alamy Stock Photo The topical gel delivers new COL7A1 genes directly to skin wounds to promote wound healing. Ms Hickey said it does not have to be applied by a medical practitioner but can be done by a trained individual or family member. 'Unfortunately, Ireland is one of the slowest countries in Europe to move from recommendation to market and it could still be between seven and 12 years before we see Vyjuvek available to people here,' she said. Advertisement Filsuvez, meanwhile, is applied to a sterile non-adhesive wound dressing or directly to the skin to ease the extreme pain of wounds caused by EB. Debra made submissions to the NCPE (National Centre for Pharmacoeconomics), which has recommended the HSE provides the gel once agreement is reached on pricing. A timeline has yet to be announced but Debra is optimistic a resolution will be found by the end of summer. The charity's chief executive, Jimmy Fearon, said its entry into the Irish market is a step in the right direction. 'The treatment for EB hasn't advanced much over time, so new treatments always bring hope,' he said. 'This is not a cure but it may reduce the equivalent of a bandage change every two weeks, providing some pain alleviation. 'What this primarily represents is hope, breaking through the glass ceiling would hopefully mean that others will follow. 'Debra and other EB charities around the world support and invest in important research but, ultimately, it's the pharmaceutical companies and venture capitalists that run the breakthrough.' Ireland is in the lowest quartile in Europe for introducing new drugs to the market, the chief executive said. 'It's an arduous process to bring a drug to market and this is a positive step,' added Mr Fearon. 'What we really need is faster progression from recommendation to market – time is of the essence for the 300 people in Ireland living in pain due to this condition.'
Irish Daily Mirror
18-05-2025
- Health
- Irish Daily Mirror
Entry of new medicine into Irish market to ease pain of incurable skin condition
The introduction of two new cutting-edge medicines are hoped to transform the treatment of a rare incurable skin condition, a charity has said. Debra, which supports 300 people living with epidermolysis bullosa (EB) in Ireland, said the entry of Filsuvez into the Irish market will ease the extreme pain endured by those with 'Butterfly Skin'. The disease is caused by the absence of proteins between the skin layers, making the skin ultra fragile and easy to wound. The charity insists that the expected introduction of the prescription medical gel before the end of the year could pave the way for gene therapy treatments, such as Vyjuvek. Sinead Hickey, head of research at Debra, said: "Where Filsuvez is a promising start, as it can offer temporary pain relief, we hope it will mark the beginning for the treatment of rare disease in Ireland. "Vyjuvek has the potential to provide life-changing wound healing for people living with Dystrophic EB, it has already proven to be very effective in the US." The topical gel delivers new COL7A1 genes directly to skin wounds to promote wound healing. Ms Hickey said it does not have to be applied by a medical practitioner but can be done by a trained individual or family member. "Unfortunately, Ireland is one of the slowest countries in Europe to move from recommendation to market and it could still be between seven and 12 years before we see Vyjuvek available to people here," she said. Filsuvez, meanwhile, is applied to a sterile non-adhesive wound dressing or directly to the skin to ease the extreme pain of wounds caused by EB. Debra made submissions to the NCPE (National Centre for Pharmacoeconomics), which has recommended the HSE provides the gel once agreement is reached on pricing. A timeline has yet to be announced but Debra is optimistic a resolution will be found by the end of summer. The charity's chief executive, Jimmy Fearon, said its entry into the Irish market is a step in the right direction. "The treatment for EB hasn't advanced much over time, so new treatments always bring hope," he said. "This is not a cure but it may reduce the equivalent of a bandage change every two weeks, providing some pain alleviation. "What this primarily represents is hope, breaking through the glass ceiling would hopefully mean that others will follow. "Debra and other EB charities around the world support and invest in important research but, ultimately, it's the pharmaceutical companies and venture capitalists that run the breakthrough." Ireland is in the lowest quartile in Europe for introducing new drugs to the market, the chief executive said. "It's an arduous process to bring a drug to market and this is a positive step," added Mr Fearon. "What we really need is faster progression from recommendation to market – time is of the essence for the 300 people in Ireland living in pain due to this condition."
BreakingNews.ie
18-05-2025
- Health
- BreakingNews.ie
Cutting-edge medicines hoped to transform treatment of incurable skin condition
The introduction of two new cutting-edge medicines are hoped to transform the treatment of a rare incurable skin condition, a charity has said. Debra, which supports 300 people living with epidermolysis bullosa (EB) in Ireland, said the entry of Filsuvez into the Irish market will ease the extreme pain endured by those with 'Butterfly Skin'. Advertisement The disease is caused by the absence of proteins between the skin layers, making the skin ultra fragile and easy to wound. The charity insists that the expected introduction of the prescription medical gel before the end of the year could pave the way for gene therapy treatments, such as Vyjuvek. Sinead Hickey, head of research at Debra, said: 'Where Filsuvez is a promising start, as it can offer temporary pain relief, we hope it will mark the beginning for the treatment of rare disease in Ireland. 'Vyjuvek has the potential to provide life-changing wound healing for people living with Dystrophic EB, it has already proven to be very effective in the US.' Advertisement Sinead Hickey, head of research at Debra, says Filsuvez is a promising start. Photo: Alejandra Livschitz/Debra The topical gel delivers new COL7A1 genes directly to skin wounds to promote wound healing. Ms Hickey said it does not have to be applied by a medical practitioner but can be done by a trained individual or family member. 'Unfortunately, Ireland is one of the slowest countries in Europe to move from recommendation to market and it could still be between seven and 12 years before we see Vyjuvek available to people here,' she said. Filsuvez, meanwhile, is applied to a sterile non-adhesive wound dressing or directly to the skin to ease the extreme pain of wounds caused by EB. Advertisement Debra made submissions to the NCPE (National Centre for Pharmacoeconomics), which has recommended the HSE provides the gel once agreement is reached on pricing. A timeline has yet to be announced but Debra is optimistic a resolution will be found by the end of summer. The charity's chief executive, Jimmy Fearon, said its entry into the Irish market is a step in the right direction. 'The treatment for EB hasn't advanced much over time, so new treatments always bring hope,' he said. Advertisement 'This is not a cure but it may reduce the equivalent of a bandage change every two weeks, providing some pain alleviation. 'What this primarily represents is hope, breaking through the glass ceiling would hopefully mean that others will follow. 'Debra and other EB charities around the world support and invest in important research but, ultimately, it's the pharmaceutical companies and venture capitalists that run the breakthrough.' Ireland Gel therapy to treat 'butterfly skin' condition we... Read More Ireland is in the lowest quartile in Europe for introducing new drugs to the market, the chief executive said. Advertisement 'It's an arduous process to bring a drug to market and this is a positive step,' added Mr Fearon. 'What we really need is faster progression from recommendation to market – time is of the essence for the 300 people in Ireland living in pain due to this condition.'
